Handelsavisen
prelaunch
Companies ›Healthcare ›301617.SZ
30
301617.SZ — Shenzhen Stock Exchange Pharmaceuticals

Shandong Boyuan Pharmaceutical & Chemical Co Ltd

¥53,33
Open in Charts → Attach watcher ⌖
— —
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,85 %
Op margin
13,4 %
ROE
10,0 %
Net margin
11,8 %
Debt / equity
0,03
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Shandong Boyuan Pharmaceutical & Chemical Co Ltd is a pharmaceutical company that generates revenue primarily through the production and sale of pharmaceutical products.

Business. Shandong Boyuan Pharmaceutical & Chemical Co Ltd (301617.SZ) is a pharmaceutical company headquartered in China that operates within the Healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
10,0 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 301617.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 301617.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Shandong Boyuan Pharmaceutical & Chemical Co Ltd (301617.SZ) is a pharmaceutical company headquartered in China that operates within the Healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 6.71, indicating that it has sufficient current assets to cover its current liabilities. However, its operating cash flow is negative at -2.97 million CNY, which may signal short-term cash flow challenges. Free cash flow is positive at 33.83 million CNY, suggesting the company is generating cash after capital expenditures.

    Profitability metrics show a return on equity of 9.97% and a return on assets of 8.93%, both of which are strong indicators of efficient use of equity and assets. These figures suggest the company is performing well in terms of profitability relative to its capital base.

    The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates.

    Looking ahead, the company is expected to maintain its current revenue trajectory, with no significant growth or decline projected in the next fiscal year. Historical revenue data does not indicate a clear upward or downward trend, suggesting a stable but potentially stagnant growth path.

    The company faces a medium liquidity risk due to its negative operating cash flow, despite a strong current ratio. The risk of dilution is assessed as low, with no significant dilution events or sources identified in the available data. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing.

    Recent filings and transcripts do not provide specific details on new product launches, regulatory changes, or strategic initiatives. The company's financial statements do not highlight any major events that would significantly impact its operations or financial position in the near term.

    Key takeaways
    • The company has a strong current ratio of 6.71, indicating good short-term liquidity.
    • Return on equity and return on assets are both above 9%, suggesting strong profitability.
    • The company's operating cash flow is negative, which may indicate short-term cash flow challenges.
    • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • The company has a low risk of dilution and a conservative capital structure with a debt-to-equity ratio of 0.03.
    • No significant growth or decline is projected for the next fiscal year, indicating a stable but potentially stagnant growth path.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥53,33
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    ¥1.73B
    Net cashⓘ
    -¥44.2M
    Current ratioⓘ
    6.7
    Debt / equityⓘ
    0.0
    ROAⓘ
    8.9%
    ROEⓘ
    10.0%
    Cash conversionⓘ
    -2.0%
    CapEx / revenueⓘ
    -5.8%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin13,4 %Above median
    Net Margin11,8 %Above median
    ROE10,0 %Above median
    Capex / Rev-5,8 %Below median
    D/E0,03Above median
    Cash Conv-0,02Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Shandong Boyuan Pharmaceutical & Chemical Co Ltd Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    301617.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage